FDA Brief

Warning letters Drugs

FDA warning letter to

OCLO LLC/OCLO Nanotechnology Science

High riskIssued May 27, 2021Posted May 28, 2021Center for Drug Evaluation and Research

OCLO LLC sold chlorine dioxide products, including OCLO 3000, as unapproved COVID-19 drugs, FDA and FTC say.

What happened

FDA and FTC reviewed the company’s website on April 15, 2021, along with a Facebook page and eCrater storefront. The review found chlorine dioxide products, including OCLO 3000, offered for sale with claims to prevent, treat, or cure COVID-19. FDA says the website was removed by the letter date, but the eCrater storefront continued to offer the products.

What FDA found

  1. The chlorine dioxide products, including OCLO 3000, were sold as drugs to prevent or treat COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded—misleadingly labeled—because their labeling and promotion make misleading drug claims.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company put these products into interstate commerce, which the law prohibits for unapproved or misbranded drugs.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that its products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA tells the company to immediately stop selling the unapproved COVID-19 products. Within 48 hours, the company must email FDA describing the specific steps taken and provide copies of related documents.

Who should pay attention

  • online sellers of chlorine dioxide or 'MMS' products
  • marketplaces that host COVID-19 treatment claims
  • brands selling oral products with antiviral or immune-booster claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk